Table 1.

Overview of study visits

Visit	V0	V1	V2	V3	V4
Time, weeks from start of intervention	−7*	−1	6	12	26
Participant information
Informed consent	X
Medical history (individual and family)	X
Inclusion and exclusion criteria	X
Pregnancy test (fertile women only)		X	X	X	X
Efficacy outcomes
HbA1c	X	X	X	X	X
Body weight	X	X	X	X	X
Waist and hip circumference		X	X	X	X
Body composition (DXA scanning)		X	X	X	X
Blood pressure and resting heart rate	X	X	X	X	X
Stool sample		X		X
Fasting blood samples		X	X	X	X
Postprandial blood samples		X		X
Indirect calorimetry		X		X
Heart rate variability (Vagus)		X		X
Mixed meal test with SmartPill		X		X
Event registration related to SmartPill		X		X
Physical activity and sleep measurement		X	X	X
Food records		X	X	X
Continuous glucose monitoring		X	X	X
Fasting food reward and biometric measurements		X	X	X	X
Postprandial food reward and biometric measurements		X		X
Questionnaires
Sociodemographic characteristics		X
Health and well-being		X	X	X	X
Physical activity		X	X	X	X
Fasting appetite sensations		X	X	X	X
Postprandial appetite sensations		X		X
Gastrointestinal symptoms		X	X	X	X
Autonomic symptoms		X
Pain		X
Sleep quality and sleepiness		X	X	X	X
Chronotype		X	X	X	X
Night eating		X	X	X	X
Eating behaviour and control over eating		X	X	X	X
Interviews
Interview†		X
Interview (participants in the TRE group)‡				X	X

*Max 6 weeks before baseline testing (V1).

†Interview regarding motivation for participation.

‡Interview regarding feasibility and maintenance.

DXA, dual-energy X-ray absorptiometry; HbA1c, glycated haemoglobin; TRE, time-restricted eating; V0, screening; V1, baseline testing; V2, mid-intervention testing (after 6 weeks); V3, post-intervention testing (after 3 months); V4, follow-up testing (after 6 months).